Why the study?
Methods for clinical pharmacologists to evaluate anti-aggregating compounds in humans and their effects on platelet behavior require clarification.
SummaryThe methods available to the clinical pharmacologist for evaluation of anti-aggregating compounds in man are briefly presented. A distinction is made between ex vivo methods (in vitro evaluation of the modified platelet adhesion or aggregation following drug administration) and strictly in vivo techniques (the bleeding time and the platelet survival time). The effects of dipyridamole, sulfinpyrazone, acetylsalicylic acid, clofibrate and dextrans on these indices of platelet behaviour are briefly described. It is emphasized that platelet function is altered in a very similar fashion following administration of either dipyridamole or sulfinpyrazone; acetylsalicylic acid however modifies platelet behaviour in a completely different manner. A possible synergism between these two types of compounds has been proposed.
No takes yet. Share an insight, caveat, or question.
Jos Vermylen (1975) conducted a review in Platelet aggregation. Anti-aggregating substances (dipyridamole, sulfinpyrazone, acetylsalicylic acid, clofibrate, dextrans) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: